A survey of breakthrough therapy designations

What's fueling the biotech engine—2012 to 2013

(2014) Saurabh (Rob) Aggarwal   NATURE BIOTECHNOLOGY

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies

(2013) Jianmeng Chen et al.   GASTROENTEROLOGY

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

(2013) Gregory T. Everson et al.   GASTROENTEROLOGY

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

(2013) Eric Lawitz et al.   LANCET

Drugs with breakthrough status charm investors

(2013) Melanie Senior   NATURE BIOTECHNOLOGY

Expediting Drug Development — The FDA's New “Breakthrough Therapy” Designation

(2013) Rachel E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

What's fueling the biotech engine—2011 to 2012

(2012) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia

(2012) Michael P. Whyte et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

(2011) John Hornberger et al.   LEUKEMIA & LYMPHOMA

Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy

(2011) Nathalie M. Goemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Institute of Medicine recommendations for the prevention and control of hepatitis B and C

(2010) Abigail E. Mitchell et al.   HEPATOLOGY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY